Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Maastricht University Medical Center
British Columbia Cancer Agency
Exelixis
Genentech, Inc.
Fate Therapeutics
Fate Therapeutics
Jules Bordet Institute